Mobile

A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic s...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-005446-11

A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantation

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and feasibility of increasing cell doses of CIK cell transfusions in adult and pediatric leukemia and MDS patients with molecular, cytogenetic or hematologic relapse after allogeneic SCT.

Critère d'inclusion

  • relapsing acute leukemia, relapsing myelodysplastic syndromes

Liens